Effects of telmisartan and valsartan on insulin resistance, visfatin and adiponectin levels in hypertensive patients with metabolic syndrome

Basit Öğe Kaydı
dc.contributor.authorSarac, S.
dc.contributor.authorSarac, Fulden
dc.contributor.authorTutuncuoglu, P.
dc.date.accessioned2019-10-27T19:55:58Z
dc.date.available2019-10-27T19:55:58Z
dc.date.issued2008
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective. The aims of this study were to compare the effect of telmisartan and valsartan on the blood and insulin sensitivity and adiponectin levels in hypertensive patients with metabolic syndrome. Patients and Methods. One hundred twenty male patients who met the criteria for metabolic syndrome defined as in ATP III enrolled in the sudy. All patients were randomized to receive treatment with telmisartan 80 mg (n=70) or valsartan 160 mg (n=50) once daily for 6 months. Serum insulin concentration was measured by chemiluminescence, plasma levels of adiponectin and visfatin by Enzyme linked immunosorbent assay kit (ELISA). Insulin resistance (IR) was estimated using the homeostasis model assessment (HOMA). Results: Mean HOMA-IR and adiponectin and visfatin levels were measured 3.00 +/- 0.9 and 5.93 +/- 0.3 mgr/ml and 23.45 +/- 6.1 mgr/ml in patients before starting treatment of telmisartan, respectively. They were changed to 2.4 +/- 0.5 and 6.71 +/- 0.5 mg/ml and 21.40 +/- 5.0 mg/ml at a 6 months period. In valsartan group, mean HOMA-IR and adiponectin and visfatin levels were measured 2.9 +/- 0.5 and 5.50 +/- 0.9 mg/ml 19.05 +/- 3.9 mg/ml before treatment, respectively. After a 6 months period, mean HOMA-IR and adiponectin and visfatin levels were found 3.00 +/- 0.9 and 6.24 +/- 0.7 mg/ml and 20.76 +/- 4.5 mg/ml, respectively. Conclusion: Telmisartan produced significant reductions from baseline in HOMA-IR and insulin levels, whereas valsartan did not. Both telmisartan and valsartan did no changed serum visfatin levels but they increased serum adiponectin concentrations by RAS blockade.en_US
dc.identifier.endpage32en_US
dc.identifier.issn1841-0987
dc.identifier.issn1841-0987en_US
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage23en_US
dc.identifier.urihttps://hdl.handle.net/11454/40757
dc.identifier.volume4en_US
dc.identifier.wosWOS:000254637500003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherEditura Acad Romaneen_US
dc.relation.ispartofActa Endocrinologica-Bucharesten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMetabolic Syndromeen_US
dc.subjecttelmisartanen_US
dc.subjectvalsartanen_US
dc.subjectadiponectinen_US
dc.subjectvisfatinen_US
dc.subjectinsulin resistanceen_US
dc.titleEffects of telmisartan and valsartan on insulin resistance, visfatin and adiponectin levels in hypertensive patients with metabolic syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu